dc.contributor.author | Kocagoz, S | |
dc.contributor.author | Akova, M | |
dc.contributor.author | Altun, B | |
dc.contributor.author | Gur, D | |
dc.contributor.author | Hascelik, G | |
dc.date.accessioned | 2019-12-10T11:14:06Z | |
dc.date.available | 2019-12-10T11:14:06Z | |
dc.date.issued | 2002 | |
dc.identifier.issn | 1198-743X | |
dc.identifier.uri | https://doi.org/10.1046/j.1469-0691.2002.00416.x | |
dc.identifier.uri | http://hdl.handle.net/11655/15129 | |
dc.description.abstract | We have evaluated the in vitro activities of seven fluoroquinolones against 69 strains of Brucella melitensis . According to their minimum inhibitory concentration for 90% growth (MIC90 ) values, the most active agent was found to be sparfloxacin (MIC90 0.12 mg/L) followed by levofloxacin, ciprofloxacin, ofloxacin (MIC90 0.50 mg/L) and grepafloxacin (MIC90 1 mg/L), gemifloxacin (MIC90 2 mg/L) and gatifloxacin (MIC90 4 mg/L). | |
dc.language.iso | en | |
dc.publisher | Blackwell Publishing Ltd | |
dc.relation.isversionof | 10.1046/j.1469-0691.2002.00416.x | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Infectious Diseases | |
dc.subject | Microbiology | |
dc.title | In Vitro Activities Of New Quinolones Against Brucella Melitensis Isolated In A Tertiary-Care Hospital In Turkey | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Clinical Microbiology And Infection | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 8 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 240 | |
dc.identifier.endpage | 242 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |